AVB-202
Asset
Delivers a functional frataxin gene using an AAV vector to restore mitochondrial frataxin expression.
- Stage
- Preclinical
- Modality
- Gene therapy
- Target
- FXN
- 1
- Indication
- 0
- Trials
- 2
- Developers
Indications
1Friedreich ataxia
Preclinical, sec.gov, Dec 5, 2022
In the full profile
- Targets and what it contains1
- Owner and partners4
- Evidence for its targets1
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.